Varex Imaging (VREX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
12 Aug, 2026Executive summary
Teledyne has announced a proposed acquisition of Varex, with both companies operating independently until the transaction closes, expected in early 2027.
Customers are assured of continuity in service, support, and contractual commitments throughout the transition period.
The transaction aims to strengthen long-term investment in technology, manufacturing, and innovation.
Forward-looking statements highlight anticipated synergies and benefits but caution about risks and uncertainties that could affect the outcome.
Voting matters and shareholder proposals
A special meeting of stockholders will be held to vote on the adoption of the Merger Agreement between Varex and Teledyne.
Stockholders are urged to review the proxy statement and related materials when available, as they will contain important information about the transaction.
Board of directors and corporate governance
Certain directors and executive officers of Varex may be deemed participants in the solicitation of proxies for the special meeting.
Information about directors, executive officers, and their security holdings is available in recent SEC filings and will be updated in the definitive proxy statement.
Latest events from Varex Imaging
- Shareholders will vote on a proposed acquisition by Teledyne Technologies, closing in early 2027.VREX
Proxy filing - Shareholders will vote on a proposed acquisition by Teledyne, expected to close in early 2027.VREX
Proxy filing - Shareholders will vote on a proposed acquisition by Teledyne, expected to close in early 2027.VREX
Proxy filing - Teledyne to acquire Varex Imaging for $18.90 per share in a $1.1B all-cash merger.VREX
Proxy filing - Quarterly revenue up 4% YoY to $211M, net income rebounded, and merger with Teledyne announced.VREX
Q3 2026 - Annual guidance, India ramp, photon counting, and AI drive growth and strategic flexibility.VREX
Jefferies Global Healthcare Conference 2026 - Q2 FY26 revenue rose 1–1.5% to $216M, with non-GAAP EPS at $0.21 and lower leverage from refinancing.VREX
Q2 2026 - Photon counting and industrial growth offset medical softness, with gradual China recovery expected.VREX
Jefferies 2024 Global Healthcare Conference - Q1 revenue up 5% to $200M, margin 35%, strong security orders, and Q2 growth outlook.VREX
Q1 2025